← Back to search results

AwardedFind a Tender · award

BH_NonClinical_Pharmacy_Car-T

Buyer: Barts Health NHS Trust →

BuyerBarts Health NHS Trust
StatusAwarded
DeadlineNot published
ValueValue not published
Published26 Nov 2025

What is being bought

CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells. The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products At the time of writing it is only offered at 8 sites across the UK. The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order. The price paid to the supplier with be capped at NICE / NHS England approved list prices.

Lot details

Lot 1

No lot description published.

Statuscomplete

Comparable-procurement analytics

No usable CPV category has been published, so a comparable market set cannot yet be built.

Procurement strategy & market signals

Framework agreementNot published
Dynamic purchasing systemNot published
Competitive procurementNot published
Recurring requirementNot published
Procurement method rationaleCAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells. The products can only be supplied by the the proposed contractor, Bristol Myers Squibb.
Rationale classificationssingleSuppliersIntellectualPropertyExclusiveRights
Special regimeNot published
Covered byNot published
Submission policyNot published
Selection criteriaNot published
Risk detailsNot published

Planning & early market engagement

BudgetNot published
No-engagement rationaleNot published
Planning documents0
Planning milestones0

No planning milestones published.

Related procurements

No linked framework, prior procurement or reprocurement published.

Awards

Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products

Statuspending
Value£2,100,000
Contract periodFrom 8 Dec 2025 to 5 Dec 2030

Documents & submission route

  • Not published

Source data inventory

Diagnostic view. “Not published” means this current release does not provide a value.

OCIDocds-h6vhtk-05e8d3
Latest release ID077086-2025
Latest release timestampWed Nov 26 2025 09:46:27 GMT+0000 (Coordinated Universal Time)
Sourcefind-a-tender
Official notice URLNot published
Tender statuscomplete
Procurement methoddirect
Procurement method detailsDirect award
Main procurement categoryNot published
Above thresholdNot published
Legal basis2023/54
Tender period: startNot published
Tender period: endNot published
Expression of interest deadlineNot published
Enquiry deadlineNot published
Award period: startNot published
Award period: endNot published
Submission method detailsNot published
Submission languagesNot published
Electronic catalogue policyNot published
Total tender valueNot published
Tender lots in source1
Tender items in source0
Tender documents in source1
Awards in latest release1
Contracts in latest release0
Parties in latest release2

Notice history

DateEventReference
26 Nov 2025award, contract077086-2025

All source data

Unmodified official OCDS data retained by Tenderline for this procurement process.

Complete current OCDS release JSON
{
  "id": "077086-2025",
  "tag": [
    "award",
    "contract"
  ],
  "date": "2025-11-26T09:46:27Z",
  "ocid": "ocds-h6vhtk-05e8d3",
  "buyer": {
    "id": "GB-PPON-PVTL-5832-LMDG",
    "name": "Barts Health NHS Trust"
  },
  "awards": [
    {
      "id": "1",
      "items": [
        {
          "id": "1",
          "relatedLot": "1",
          "additionalClassifications": [
            {
              "id": "33000000",
              "scheme": "CPV",
              "description": "Medical equipments, pharmaceuticals and personal care products"
            },
            {
              "id": "85149000",
              "scheme": "CPV",
              "description": "Pharmacy services"
            }
          ]
        }
      ],
      "title": "Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products",
      "value": {
        "amount": 2100000,
        "currency": "GBP",
        "amountGross": 2520000
      },
      "status": "pending",
      "options": {
        "description": "Extension option"
      },
      "renewal": {
        "description": "Option to extend contract by a further 5 years"
      },
      "documents": [
        {
          "id": "077086-2025",
          "url": "https://www.find-tender.service.gov.uk/Notice/077086-2025",
          "format": "text/html",
          "noticeType": "UK5",
          "description": "Transparency notice on Find a Tender",
          "documentType": "awardNotice",
          "datePublished": "2025-11-26T09:46:27Z"
        }
      ],
      "suppliers": [
        {
          "id": "GB-COH-02487574",
          "name": "Bristol Myers Squibb"
        }
      ],
      "hasOptions": true,
      "hasRenewal": true,
      "milestones": [
        {
          "id": "1",
          "type": "futureSignatureDate",
          "status": "scheduled",
          "dueDate": "2025-12-08T23:59:59Z"
        }
      ],
      "relatedLots": [
        "1"
      ],
      "aboveThreshold": true,
      "contractPeriod": {
        "endDate": "2030-12-05T23:59:59Z",
        "startDate": "2025-12-08T00:00:00Z",
        "maxExtentDate": "2035-12-07T23:59:59Z"
      },
      "mainProcurementCategory": "services"
    }
  ],
  "tender": {
    "id": "C402343",
    "lots": [
      {
        "id": "1",
        "status": "complete"
      }
    ],
    "title": "BH_NonClinical_Pharmacy_Car-T",
    "status": "complete",
    "documents": [
      {
        "id": "conflictOfInterest",
        "description": "Not published",
        "documentType": "conflictOfInterest"
      }
    ],
    "legalBasis": {
      "id": "2023/54",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents",
      "scheme": "UKPGA"
    },
    "description": "CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a  new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.\nThe proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products\nAt the time of writing it is only offered at 8 sites across the UK.\nThe proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.\nThe price paid to the supplier with be capped at NICE / NHS England approved list prices.",
    "procurementMethod": "direct",
    "procurementMethodDetails": "Direct award",
    "procurementMethodRationale": "CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a  new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.\nThe products can only be supplied by the the proposed contractor, Bristol Myers Squibb.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "singleSuppliersIntellectualPropertyExclusiveRights"
      }
    ]
  },
  "parties": [
    {
      "id": "GB-PPON-PVTL-5832-LMDG",
      "name": "Barts Health NHS Trust",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKI42",
        "country": "GB",
        "locality": "London",
        "postalCode": "E14 5HJ",
        "countryName": "United Kingdom",
        "streetAddress": "20 Churchill Place, Canary Wharf"
      },
      "details": {
        "url": "https://www.bartshealth.nhs.uk",
        "classifications": [
          {
            "id": "publicAuthorityCentralGovernment",
            "scheme": "UK_CA_TYPE",
            "description": "Public authority - central government"
          }
        ]
      },
      "identifier": {
        "id": "PVTL-5832-LMDG",
        "scheme": "GB-PPON"
      },
      "contactPoint": {
        "email": "oliver.watling@nhs.net"
      }
    },
    {
      "id": "GB-COH-02487574",
      "name": "Bristol Myers Squibb",
      "roles": [
        "supplier"
      ],
      "address": {
        "region": "UKJ13",
        "country": "GB",
        "locality": "Denham",
        "postalCode": "UB8 1DH",
        "countryName": "United Kingdom",
        "streetAddress": "Arc Uxbridge Sanderson Road,   New Denham,"
      },
      "details": {
        "vcse": false,
        "scale": "large"
      },
      "identifier": {
        "id": "02487574",
        "scheme": "GB-COH"
      },
      "contactPoint": {
        "email": "jon.joyce@bms.com"
      }
    }
  ],
  "language": "en",
  "initiationType": "tender"
}
Complete JSON history (1 releases)
26 Nov 2025 · 077086-2025 · award, contract
{
  "id": "077086-2025",
  "tag": [
    "award",
    "contract"
  ],
  "date": "2025-11-26T09:46:27Z",
  "ocid": "ocds-h6vhtk-05e8d3",
  "buyer": {
    "id": "GB-PPON-PVTL-5832-LMDG",
    "name": "Barts Health NHS Trust"
  },
  "awards": [
    {
      "id": "1",
      "items": [
        {
          "id": "1",
          "relatedLot": "1",
          "additionalClassifications": [
            {
              "id": "33000000",
              "scheme": "CPV",
              "description": "Medical equipments, pharmaceuticals and personal care products"
            },
            {
              "id": "85149000",
              "scheme": "CPV",
              "description": "Pharmacy services"
            }
          ]
        }
      ],
      "title": "Provision of CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) products",
      "value": {
        "amount": 2100000,
        "currency": "GBP",
        "amountGross": 2520000
      },
      "status": "pending",
      "options": {
        "description": "Extension option"
      },
      "renewal": {
        "description": "Option to extend contract by a further 5 years"
      },
      "documents": [
        {
          "id": "077086-2025",
          "url": "https://www.find-tender.service.gov.uk/Notice/077086-2025",
          "format": "text/html",
          "noticeType": "UK5",
          "description": "Transparency notice on Find a Tender",
          "documentType": "awardNotice",
          "datePublished": "2025-11-26T09:46:27Z"
        }
      ],
      "suppliers": [
        {
          "id": "GB-COH-02487574",
          "name": "Bristol Myers Squibb"
        }
      ],
      "hasOptions": true,
      "hasRenewal": true,
      "milestones": [
        {
          "id": "1",
          "type": "futureSignatureDate",
          "status": "scheduled",
          "dueDate": "2025-12-08T23:59:59Z"
        }
      ],
      "relatedLots": [
        "1"
      ],
      "aboveThreshold": true,
      "contractPeriod": {
        "endDate": "2030-12-05T23:59:59Z",
        "startDate": "2025-12-08T00:00:00Z",
        "maxExtentDate": "2035-12-07T23:59:59Z"
      },
      "mainProcurementCategory": "services"
    }
  ],
  "tender": {
    "id": "C402343",
    "lots": [
      {
        "id": "1",
        "status": "complete"
      }
    ],
    "title": "BH_NonClinical_Pharmacy_Car-T",
    "status": "complete",
    "documents": [
      {
        "id": "conflictOfInterest",
        "description": "Not published",
        "documentType": "conflictOfInterest"
      }
    ],
    "legalBasis": {
      "id": "2023/54",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents",
      "scheme": "UKPGA"
    },
    "description": "CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a  new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.\nThe proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products\nAt the time of writing it is only offered at 8 sites across the UK.\nThe proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.\nThe price paid to the supplier with be capped at NICE / NHS England approved list prices.",
    "procurementMethod": "direct",
    "procurementMethodDetails": "Direct award",
    "procurementMethodRationale": "CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a  new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.\nThe products can only be supplied by the the proposed contractor, Bristol Myers Squibb.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "singleSuppliersIntellectualPropertyExclusiveRights"
      }
    ]
  },
  "parties": [
    {
      "id": "GB-PPON-PVTL-5832-LMDG",
      "name": "Barts Health NHS Trust",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKI42",
        "country": "GB",
        "locality": "London",
        "postalCode": "E14 5HJ",
        "countryName": "United Kingdom",
        "streetAddress": "20 Churchill Place, Canary Wharf"
      },
      "details": {
        "url": "https://www.bartshealth.nhs.uk",
        "classifications": [
          {
            "id": "publicAuthorityCentralGovernment",
            "scheme": "UK_CA_TYPE",
            "description": "Public authority - central government"
          }
        ]
      },
      "identifier": {
        "id": "PVTL-5832-LMDG",
        "scheme": "GB-PPON"
      },
      "contactPoint": {
        "email": "oliver.watling@nhs.net"
      }
    },
    {
      "id": "GB-COH-02487574",
      "name": "Bristol Myers Squibb",
      "roles": [
        "supplier"
      ],
      "address": {
        "region": "UKJ13",
        "country": "GB",
        "locality": "Denham",
        "postalCode": "UB8 1DH",
        "countryName": "United Kingdom",
        "streetAddress": "Arc Uxbridge Sanderson Road,   New Denham,"
      },
      "details": {
        "vcse": false,
        "scale": "large"
      },
      "identifier": {
        "id": "02487574",
        "scheme": "GB-COH"
      },
      "contactPoint": {
        "email": "jon.joyce@bms.com"
      }
    }
  ],
  "language": "en",
  "initiationType": "tender"
}